Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents.

Hagerman R, Jacquemont S, Berry-Kravis E, Des Portes V, Stanfield A, Koumaras B, Rosenkranz G, Murgia A, Wolf C, Apostol G, von Raison F.

Sci Rep. 2018 Nov 19;8(1):16970. doi: 10.1038/s41598-018-34978-4.

2.

Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension study.

Bailey DB Jr, Berry-Kravis E, Wheeler A, Raspa M, Merrien F, Ricart J, Koumaras B, Rosenkranz G, Tomlinson M, von Raison F, Apostol G.

J Neurodev Disord. 2016;8:1. doi: 10.1186/s11689-015-9134-5. Epub 2015 Dec 15.

3.

Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials.

Berry-Kravis E, Des Portes V, Hagerman R, Jacquemont S, Charles P, Visootsak J, Brinkman M, Rerat K, Koumaras B, Zhu L, Barth GM, Jaecklin T, Apostol G, von Raison F.

Sci Transl Med. 2016 Jan 13;8(321):321ra5. doi: 10.1126/scitranslmed.aab4109.

PMID:
26764156
4.

Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32).

Olin JT, Bhatnagar V, Reyes P, Koumaras B, Meng X, Brannan S.

Int J Geriatr Psychiatry. 2010 Apr;25(4):419-26. doi: 10.1002/gps.2355.

PMID:
19670390
5.

Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer's disease.

Sadowsky CH, Dengiz A, Olin JT, Koumaras B, Meng X, Brannan S; US38 study group.

Am J Alzheimers Dis Other Demen. 2009 Jun-Jul;24(3):267-75. doi: 10.1177/1533317509333037. Epub 2009 Mar 16.

PMID:
19293130
6.

Long-term effects of rivastigmine capsules in patients with traumatic brain injury.

Silver JM, Koumaras B, Meng X, Potkin SG, Reyes PF, Harvey PD, Katz DI, Gunay I, Arciniegas DB.

Brain Inj. 2009 Feb;23(2):123-32. doi: 10.1080/02699050802649696.

PMID:
19191091
7.

Long-term safety and tolerability of rivastigmine in patients with Alzheimer's disease switched from donepezil: an open-label extension study.

Figiel GS, Koumaras B, Meng X, Strigas J, Gunay I.

Prim Care Companion J Clin Psychiatry. 2008;10(5):363-7.

8.

Safety and efficacy of rivastigmine in patients with Alzheimer's disease not responding adequately to donepezil: an open-label study.

Figiel GS, Sadowsky CH, Strigas J, Koumaras B, Meng X, Gunay I.

Prim Care Companion J Clin Psychiatry. 2008;10(4):291-8.

9.

Long-term effects of rivastigmine treatment on the need for psychotropic medications in nursing home patients with Alzheimer's disease : results of a 52-week open-label study.

Edwards K, Koumaras B, Chen M, Gunay I, Mirski D; Rivastigmine Nursing Home Study Team*.

Clin Drug Investig. 2005;25(8):507-15.

PMID:
17532694
10.

Effects of rivastigmine on cognitive function in patients with traumatic brain injury.

Silver JM, Koumaras B, Chen M, Mirski D, Potkin SG, Reyes P, Warden D, Harvey PD, Arciniegas D, Katz DI, Gunay I.

Neurology. 2006 Sep 12;67(5):748-55.

PMID:
16966534
11.

A pilot study evaluating the efficacy and safety of rivastigmine in patients with mixed dementia.

Potkin SG, Alva G, Gunay I, Koumaras B, Chen M, Mirski D.

Drugs Aging. 2006;23(3):241-9.

PMID:
16608379
12.
14.

Switching From Donepezil to Rivastigmine Is Well Tolerated: Results of an Open-Label Safety and Tolerability Study.

Sadowsky CH, Farlow MR, Atkinson L, Steadman J, Koumaras B, Chen M, Mirski D.

Prim Care Companion J Clin Psychiatry. 2005;7(2):43-48.

16.

Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.

Farlow M, Potkin S, Koumaras B, Veach J, Mirski D.

Arch Neurol. 2003 Jun;60(6):843-8.

PMID:
12810489

Supplemental Content

Loading ...
Support Center